Responses
Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)
Compose a Response to This Article
Other responses
No responses have been published for this article.